首页/数据集/Dataset from Efficacy, Tolerability and Safety of Galantamine in the Treatment of Alzheimer's Disease

Dataset from Efficacy, Tolerability and Safety of Galantamine in the Treatment of Alzheimer's Disease

NIAID Data Ecosystem2026-05-10 收录

阿尔茨海默病药物

加兰他敏疗效评估

数据链接：

https://doi.org/10.25934/00004680 数据链接链接失效反馈

官方服务：

资源简介：

The purpose of this study is to evaluate the safety and effectiveness of two doses of galantamine (a drug for treating dementia) versus placebo in the treatment of patients with Alzheimer's disease.

应用场景：

创建时间：

2025-11-20

阿尔茨海默病药物

局部药物递送

There are many steps involved in the molecular cascade that causes the clinical symptoms of Alzheimer’s disease, and identifying which step to try to block is complex. Recently, a critical step in the

Monash University Figshare2026-02-11 更新80

The transition midpoint temperature (Tm) calculated from DSC curves of Aβ42 in absence and presence of doliroside A.

蛋白质热稳定性分析

阿尔茨海默病药物

The transition midpoint temperature (Tm) calculated from DSC curves of Aβ42 in absence and presence of doliroside A.

Figshare2017-10-31 更新40

Development of Second-Generation Phenoxyethylpiperidines as Potent Sigma-1 Receptor Agonists with Neuroprotective Potential for Alzheimer’s Disease

阿尔茨海默病药物

Sigma-1受体

Sigma-1 receptor (S1R) is a “pluripotent chaperone” associated with pro-survival functions. Pieces of evidence show it as a promising therapeutic target for treating neurodegeneration. Encouraging res

Figshare2026-02-05 更新10

Systematic Review: Representativeness of Participants in RCTs of Acetylcholinesterase Inhibitors

阿尔茨海默病药物

临床试验代表性评估

Objective To determine whether there are differences in age and sex distribution and presence of comorbidities between participants included in randomized controlled trials of acetylcholinesterase inh

NIAID Data Ecosystem80

Dataset from Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease With Option for up to an Additional Two Years of Treatment and an Open-Label Extension With Active Study Treatment

阿尔茨海默病药物

前驱期认知功能评估

This multi-center, randomized, double-blind, placebo-controlled parallel-group study will evaluate the effect of gantenerumab (RO4909832) on cognition and functioning and the safety and pharmacokine

NIAID Data Ecosystem20

Dataset from Efficacy, Tolerability and Safety of Galantamine in the Treatment of Alzheimer's Disease

资源简介：

相关数据集